Grey James, Jones Dominic, Wilson Laura, Nakjang Sirintra, Clayton Jake, Temperley Richard, Clark Emma, Gaughan Luke, Robson Craig
Northern Institute for Cancer Research, The Medical School, Newcastle University, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK.
Oncotarget. 2017 Dec 4;9(3):3922-3935. doi: 10.18632/oncotarget.22883. eCollection 2018 Jan 9.
The Androgen Receptor (AR) is a key molecule in the development, maintenance and progression of prostate cancer (PC). However, the relationship between the AR and co-regulatory proteins that facilitate AR activity in castrate resistant settings remain understudied. Here we show that protein phosphatase 1 regulatory subunits, identified from a phosphatase RNAi screen, direct PP1 catalytic subunits to a varied yet significant response in AR function. As such, we have characterised the PP1β holoenzyme, myosin phosphatase (MLCP), as a novel ligand independent regulator of the AR. Sustained MLCP activity through down-regulation of the MLCP inhibitory subunit, PPP1R14C, results in impaired AR nuclear translocation, protein stability and transcriptional activity in distinct models of PC progression, culminating in restoration of a non-malignant prostate genotype. Phenotypically, a marked reduction in cell proliferation and migration, characterised by G1 cell cycle arrest is observed, confirming PP1 holoenzyme disruption as a novel treatment approach in PC.
雄激素受体(AR)是前列腺癌(PC)发生、维持和进展过程中的关键分子。然而,在去势抵抗情况下,AR与促进AR活性的共调节蛋白之间的关系仍未得到充分研究。在此,我们表明,从磷酸酶RNA干扰筛选中鉴定出的蛋白磷酸酶1调节亚基,可使PP1催化亚基对AR功能产生多样但显著的反应。因此,我们将PP1β全酶,即肌球蛋白磷酸酶(MLCP),鉴定为AR的一种新型非配体依赖性调节因子。在不同的PC进展模型中,通过下调MLCP抑制亚基PPP1R14C来维持MLCP活性,会导致AR核转位、蛋白质稳定性和转录活性受损,最终恢复非恶性前列腺基因型。从表型上看,观察到细胞增殖和迁移显著减少,其特征为G1期细胞周期停滞,证实PP1全酶破坏是PC的一种新型治疗方法。